VectivBio Enters Licensing Deal with Asahi Kasei and $100 Million Plus in New Funding globalgenes.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globalgenes.org Daily Mail and Mail on Sunday newspapers.
Exclusive License with Asahi Kasei Pharma to develop and commercialize Apraglutide in Japan includes $30 million upfront cash payment, eligibility for up to $170 million in development and commercial. | March 30, 2022
VectivBio Appoints Scott Applebaum as Chief Legal Officer & Corporate Secretary kulr8.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kulr8.com Daily Mail and Mail on Sunday newspapers.